427 studies found for:    United States, Vermont | University of Vermont
Show Display Options
Rank Status Study
21 Unknown  Bone Turnover in Type 2 Diabetes Patients
Condition: Type 2 Diabetes
Interventions: Drug: Sitagliptin;   Drug: Placebo
22 Terminated Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride
Condition: Chronic Kidney Failure
Interventions: Drug: Fermagate;   Drug: Sevelamer hydrochloride
23 Active, not recruiting Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Biological: therapeutic immune globulin;   Other: clinical observation;   Drug: cyclophosphamide;   Drug: prednisone;   Procedure: magnetic resonance imaging;   Other: laboratory biomarker analysis;   Drug: Corticotropin-Releasing Hormone
24 Active, not recruiting Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Conditions: Adult Malignant Mesenchymoma;   Adult Rhabdomyosarcoma;   Alveolar Childhood Rhabdomyosarcoma;   Childhood Malignant Mesenchymoma;   Embryonal Childhood Rhabdomyosarcoma;   Embryonal-botryoid Childhood Rhabdomyosarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma
Interventions: Drug: irinotecan hydrochloride;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis;   Other: questionnaire administration
25 Active, not recruiting Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Intervention: Drug: dasatinib
26 Suspended Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Neurofibrosarcoma;   Chondrosarcoma;   Endometrial Stromal Sarcoma;   Mast Cell Sarcoma;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Ovarian Carcinosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: alisertib;   Other: laboratory biomarker analysis
27 Active, not recruiting Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission
Condition: Childhood Acute Lymphoblastic Leukemia in Remission
Interventions: Behavioral: compliance monitoring;   Other: study of socioeconomic and demographic variables;   Drug: mercaptopurine tablet;   Drug: methotrexate
28 Terminated Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009)
Conditions: Adenocarcinoma of the Rectum;   Stage II Rectal Cancer;   Stage III Rectal Cancer
Interventions: Drug: oxaliplatin;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: bevacizumab;   Procedure: laboratory biomarker analysis
29 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Childhood Acute Basophilic Leukemia;   Childhood Acute Eosinophilic Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: thioguanine;   Drug: etoposide;   Other: laboratory biomarker analysis
30 Recruiting Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate;   Drug: cytarabine;   Drug: etoposide;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
31 Active, not recruiting
Has Results
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: paclitaxel;   Drug: carboplatin
32 Enrolling by invitation Registry of Pregnancies Conceived Following Exposure to Ovulation Stimulation Medications
Condition: Infertility
Intervention:
33 Active, not recruiting
Has Results
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Conditions: Adult Rhabdomyosarcoma;   Embryonal Childhood Rhabdomyosarcoma;   Embryonal-botryoid Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma
Interventions: Procedure: conventional surgery;   Drug: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Radiation: radiation therapy
34 Active, not recruiting Not Quite Ready to Quit
Condition: Smoking Cessation
Interventions: Behavioral: Usual care;   Behavioral: Reduction;   Behavioral: 5Rs
35 Terminated Efficacy of Prednisone In the Treatment of Ocular Myasthenia
Condition: Ocular Myasthenia Gravis
Interventions: Drug: Prednisone;   Drug: Placebo
36 Recruiting Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment
Condition: Cystic Fibrosis
Intervention: Other: Adults - CFPE Treatment
37 Completed Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome
Conditions: Infant, Newborn;   Infant, Low Birth Weight;   Infant, Small for Gestational Age;   Infant, Premature;   Bronchopulmonary Dysplasia
Interventions: Drug: Exosurf;   Drug: Survanta
38 Unknown  Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation (NIPPV)
Condition: Amyotrophic Lateral Sclerosis
Intervention: Device: BiPAP
39 Active, not recruiting Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: everolimus;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
40 Active, not recruiting
Has Results
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Biological: rituximab;   Drug: lenalidomide

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years